APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antidiabetic SGLT-2 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antidiabetic SGLT-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

20 December 2025196 pages

Choose your research edition.

Industry ResearchAntidiabetic SGLT-2 Inhibitor Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Antidiabetic SGLT-2 Inhibitor Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Antidiabetic SGLT-2 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antidiabetic SGLT-2 Inhibitor Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antidiabetic SGLT-2 Inhibitor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Antidiabetic SGLT-2 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antidiabetic SGLT-2 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antidiabetic SGLT-2 Inhibitor include Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, Servier Laboratories, AstraZeneca, GlaxoSmithKline, Pfizer, Eli Lilly and Merck & Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antidiabetic SGLT-2 Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antidiabetic SGLT-2 Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antidiabetic SGLT-2 Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antidiabetic SGLT-2 Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Antidiabetic SGLT-2 Inhibitor Segment by Company

Boehringer Ingelheim

Bristol-Myers Squibb

Novo Nordisk

Servier Laboratories

AstraZeneca

GlaxoSmithKline

Pfizer

Eli Lilly

Merck & Co

Johnson & Johnson

Sanofi

Takeda Pharmaceuticals

Antidiabetic SGLT-2 Inhibitor Segment by Type

Canagliflozin

Dapagliflozin

Empagliflozin

Other

Antidiabetic SGLT-2 Inhibitor Segment by Application

Hospitals

Clinics

Other

Antidiabetic SGLT-2 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antidiabetic SGLT-2 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antidiabetic SGLT-2 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antidiabetic SGLT-2 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antidiabetic SGLT-2 Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antidiabetic SGLT-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antidiabetic SGLT-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antidiabetic SGLT-2 Inhibitor Industry Trends Table 2. Antidiabetic SGLT-2 Inhibitor Industry Drivers Table 3. Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges Table 4. Antidiabetic SGLT-2 Inhibitor Industry Restraints Table 5. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers Table 9. Global Antidiabetic SGLT-2 Inhibitor Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antidiabetic SGLT-2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antidiabetic SGLT-2 Inhibitor Manufacturers, Product Type & Application Table 13. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antidiabetic SGLT-2 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Canagliflozin Table 17. Major Manufacturers of Dapagliflozin Table 18. Major Manufacturers of Empagliflozin Table 19. Major Manufacturers of Other Table 20. Global Antidiabetic SGLT-2 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2026) & (K Units) Table 22. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2027-2032) & (K Units) Table 23. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2026) Table 24. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2027-2032) Table 25. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2026) & (K Units) Table 27. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2027-2032) & (K Units) Table 28. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2026) Table 29. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospitals Table 31. Major Manufacturers of Clinics Table 32. Major Manufacturers of Other Table 33. Global Antidiabetic SGLT-2 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2026) & (K Units) Table 35. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2027-2032) & (K Units) Table 36. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2026) Table 37. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2027-2032) Table 38. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2026) & (K Units) Table 40. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2027-2032) & (K Units) Table 41. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2026) Table 42. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2027-2032) Table 43. Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2026) & (K Units) Table 45. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global Antidiabetic SGLT-2 Inhibitor Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Antidiabetic SGLT-2 Inhibitor Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 50. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 51. Europe Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 53. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2027-2032) & (K Units) Table 60. Global Antidiabetic SGLT-2 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2021-2026) Table 64. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2027-2032) Table 65. Boehringer Ingelheim Company Information Table 66. Boehringer Ingelheim Business Overview Table 67. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 69. Boehringer Ingelheim Recent Development Table 70. Bristol-Myers Squibb Company Information Table 71. Bristol-Myers Squibb Business Overview Table 72. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 74. Bristol-Myers Squibb Recent Development Table 75. Novo Nordisk Company Information Table 76. Novo Nordisk Business Overview Table 77. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 79. Novo Nordisk Recent Development Table 80. Servier Laboratories Company Information Table 81. Servier Laboratories Business Overview Table 82. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 84. Servier Laboratories Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 89. AstraZeneca Recent Development Table 90. GlaxoSmithKline Company Information Table 91. GlaxoSmithKline Business Overview Table 92. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 94. GlaxoSmithKline Recent Development Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 99. Pfizer Recent Development Table 100. Eli Lilly Company Information Table 101. Eli Lilly Business Overview Table 102. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 104. Eli Lilly Recent Development Table 105. Merck & Co Company Information Table 106. Merck & Co Business Overview Table 107. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 109. Merck & Co Recent Development Table 110. Johnson & Johnson Company Information Table 111. Johnson & Johnson Business Overview Table 112. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 114. Johnson & Johnson Recent Development Table 115. Sanofi Company Information Table 116. Sanofi Business Overview Table 117. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 119. Sanofi Recent Development Table 120. Takeda Pharmaceuticals Company Information Table 121. Takeda Pharmaceuticals Business Overview Table 122. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio Table 124. Takeda Pharmaceuticals Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Antidiabetic SGLT-2 Inhibitor Distributors List Table 128. Antidiabetic SGLT-2 Inhibitor Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Antidiabetic SGLT-2 Inhibitor Product Image Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Antidiabetic SGLT-2 Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Antidiabetic SGLT-2 Inhibitor Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antidiabetic SGLT-2 Inhibitor Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Canagliflozin Image Figure 9. Dapagliflozin Image Figure 10. Empagliflozin Image Figure 11. Other Image Figure 12. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2032) Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Other Image Figure 21. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2032) Figure 24. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2032) Figure 27. North America Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 29. U.S. Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 34. Germany Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 41. China Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2021-2032) Figure 49. Brazil Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Antidiabetic SGLT-2 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 60. North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 62. Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Antidiabetic SGLT-2 Inhibitor Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Antidiabetic SGLT-2 Inhibitor Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novo Nordisk
  • Servier Laboratories
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Merck & Co
  • Johnson & Johnson
  • Sanofi
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antidiabetic SGLT-2 Inhibitor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antidiabetic SGLT-2 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antidiabetic SGLT-2 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antidiabetic SGLT-2 Inhibitor Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antidiabetic SGLT-2 Inhibitor Market Dynamics
  1. 2.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
  2. 2.2 Antidiabetic SGLT-2 Inhibitor Industry Drivers
  3. 2.3 Antidiabetic SGLT-2 Inhibitor Industry Opportunities and Challenges
  4. 2.4 Antidiabetic SGLT-2 Inhibitor Industry Restraints
3 Antidiabetic SGLT-2 Inhibitor Market by Manufacturers
  1. 3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antidiabetic SGLT-2 Inhibitor Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antidiabetic SGLT-2 Inhibitor Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antidiabetic SGLT-2 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antidiabetic SGLT-2 Inhibitor Manufacturers, Product Type & Application
  7. 3.7 Global Antidiabetic SGLT-2 Inhibitor Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antidiabetic SGLT-2 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antidiabetic SGLT-2 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antidiabetic SGLT-2 Inhibitor Tier 1, Tier 2, and Tier 3
4 Antidiabetic SGLT-2 Inhibitor Market by Type
  1. 4.1 Antidiabetic SGLT-2 Inhibitor Type Introduction
  2. 4.1.1 Canagliflozin
  3. 4.1.2 Dapagliflozin
  4. 4.1.3 Empagliflozin
  5. 4.1.4 Other
  6. 4.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Type
  7. 4.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2021-2032)
  9. 4.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2021-2032)
  10. 4.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type
  11. 4.3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2021-2032)
  13. 4.3.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2021-2032)
5 Antidiabetic SGLT-2 Inhibitor Market by Application
  1. 5.1 Antidiabetic SGLT-2 Inhibitor Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application
  6. 5.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2021-2032)
  8. 5.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application
  10. 5.3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2021-2032)
  12. 5.3.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2021-2032)
6 Global Antidiabetic SGLT-2 Inhibitor Sales by Region
  1. 6.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2021-2026)
  4. 6.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region
  1. 7.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region
  2. 7.1.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2021-2026)
  4. 7.1.3 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2027-2032)
  5. 7.1.4 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032)
  8. 7.2.2 North America Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032)
  11. 7.3.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Bristol-Myers Squibb
  8. 8.2.1 Bristol-Myers Squibb Company Information
  9. 8.2.2 Bristol-Myers Squibb Business Overview
  10. 8.2.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
  12. 8.2.5 Bristol-Myers Squibb Recent Developments
  13. 8.3 Novo Nordisk
  14. 8.3.1 Novo Nordisk Company Information
  15. 8.3.2 Novo Nordisk Business Overview
  16. 8.3.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
  18. 8.3.5 Novo Nordisk Recent Developments
  19. 8.4 Servier Laboratories
  20. 8.4.1 Servier Laboratories Company Information
  21. 8.4.2 Servier Laboratories Business Overview
  22. 8.4.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
  24. 8.4.5 Servier Laboratories Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Merck & Co
  50. 8.9.1 Merck & Co Company Information
  51. 8.9.2 Merck & Co Business Overview
  52. 8.9.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
  54. 8.9.5 Merck & Co Recent Developments
  55. 8.10 Johnson & Johnson
  56. 8.10.1 Johnson & Johnson Company Information
  57. 8.10.2 Johnson & Johnson Business Overview
  58. 8.10.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
  60. 8.10.5 Johnson & Johnson Recent Developments
  61. 8.11 Sanofi
  62. 8.11.1 Sanofi Company Information
  63. 8.11.2 Sanofi Business Overview
  64. 8.11.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
  66. 8.11.5 Sanofi Recent Developments
  67. 8.12 Takeda Pharmaceuticals
  68. 8.12.1 Takeda Pharmaceuticals Company Information
  69. 8.12.2 Takeda Pharmaceuticals Business Overview
  70. 8.12.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
  72. 8.12.5 Takeda Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antidiabetic SGLT-2 Inhibitor Value Chain Analysis
  2. 9.1.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
  6. 9.2 Antidiabetic SGLT-2 Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
  9. 9.2.3 Antidiabetic SGLT-2 Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst